– Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome – – Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 – CARLSBAD, Calif.
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe Ionis plans to independently bring donidalorsen to U.S. patients, if approved CARLSBAD, Calif. , June 18, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc.
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
CARLSBAD, Calif. , June 17, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at the virtual TD Cowen Genetic Medicines & RNA Summit on Thursday, June 20, 2024 . A live webcast of this presentation can be accessed
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over time In first-of-its-kind prospective analysis, patients switching
Ionis to hold donidalorsen Phase 3 data webcast
Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif. , May 28, 2024 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Friday, May 31 th at 8:00 a.m. Eastern Time to discuss the donidalorsen Phase 3 OASIS-HAE and